If you are in an emergency, in crisis or need someone to talk to, there is help.

View Crisis Resources
Skip to content
  • Contact Us
  • No One Left Behind
  • Join our team
  • Referral Form
  • Virtual Urgent Care
  • Accessibility
CAMH logo
  • Patients and Families
    • Main Page
    • Access CAMH & Referral Form
      • Access CAMH

        Centralized information, intake and scheduling. Access CAMH makes it easy to find support – simply call 416-535-8501, option 2.

      • Referral Form

        For mental health services, a referral form needs to be completed by a healthcare provider. For addictions services, patient can self-refer.

    • Programs & Services
      • Addictions/Substance Use
      • Alzheimer’s & Dementia
      • Anxiety & Depression
      • Concurrent Disorders
      • Developmental Disabilities
      • Mood & Personality Disorders
      • Problem Gambling
      • Schizophrenia & Psychosis
      • Trauma & Stress Disorders
      • Virtual Mental Health and Outreach
      • Other
    • Information for Patients
      • Patient Wellness and Patient Engagement at CAMH
      • What to expect
      • Your Rights
      • Patient and Family Feedback
      • Visiting CAMH

        Planning on visiting CAMH? Find contact information, directions and accessibility for each of our three main sites.

    • Information for Families
      • Family Resource Centre
      • Patient and Family Feedback
      • Visiting CAMH

        Planning on visiting CAMH? Find contact information, directions and accessibility for each of our three main sites.

    • Patient and Family Engagement
      • Patient and Family Partners Program
      • Information and resources
      • Get Involved in Research
      • Volunteer at CAMH
    • Visiting CAMH
      • Visiting CAMH

        Planning on visiting CAMH? Find contact information, directions and accessibility for each of our three main sites.

        Read More
    • MyCAMH
  • Health Info
    • Main Page
    • Mental Illness & Addiction Index
      • Conditions & Disorders
      • Medication Therapies
      • Substance Use
      • Types of Treatment
      • Information in Other Languages
    • Mental Health 101
      • Mental Health 101

        Use this series of free online tutorials as the starting point to learn about and understand a wide range of mental health topics.

        Read More
    • Guides & Publications
      • Guides & Publications

        Accessible, reliable, professionally produced resources on an array of mental health topics for patients, families, students and professionals.

        Read More
    • Crisis Resources
      • Crisis Resources

        If you are in an emergency, in crisis or need someone to talk to, there is a list of resources available for areas in and around Toronto.

        Read More
    • CAMH Store
      • CAMH Store

        The CAMH Store offers a wide array of mental illness and addiction resources for patients, families, students and professionals. Search or browse our catalogue of brochures and booklets, textbooks, manuals and assessment tools.

        Read More
    • CAMH Library
      • CAMH Library

        Open to professionals and the general public, our comprehensive resources and services support and enhance CAMH's research and clinical programs, and they facilitate learning, dynamic knowledge exchange and health promotion initiatives.

        Read More
    • Workplace Mental Health Playbook
    • Mental Health and the COVID-19 Pandemic
      • Coping with stress & anxiety
      • Quarantine & isolation
      • Stigma and prejudice
      • Loss, grief and healing
      • Covid-19 Resources for Health Care Workers
  • Research
    • Main Page
    • Research to Drive Change
    • The Discovery Fund
      • The Discovery Fund

        Fuelling the next generation of groundbreaking research and innovation dedicated to finding the causes of and cures for mental illness.

        Read More
    • Research Centres
      • Azrieli Adult Neurodevelopmental Centre
      • Azrieli Centre for Neuro-Radiochemistry
      • Brain Health Imaging Centre
      • Centre for Youth Bipolar Disorder
      • Cundill Centre for Child and Youth Depression
      • Institute for Mental Health Policy Research
      • Krembil Centre for Neuroinformatics
      • Slaight Family Centre for Youth in Transition
      • Tanenbaum Centre for Pharmacogenetics
      • Temerty Centre for Therapeutic Brain Intervention
      • The Margaret and Wallace McCain Centre for Child Youth & Family Mental Health
    • Clinical Divisions
      • Addictions Division
      • Adult Neurodevelopmental and Geriatric Psychiatry Division
      • Child and Youth Psychiatry Division
      • Forensic Psychiatry Division
      • General and Health Systems Psychiatry Division
      • Psychology Division
      • Schizophrenia Division
    • Participate in Research
      • Research Connect FAQs
      • Research Ethics
    • Research Ethics
    • Koerner Centre for Research Training
      • Koerner Centre for Research Training

        Each year CAMH provides opportunities to the next generation of scientists: today’s undergraduate students, graduate students and postdoctoral researchers. Train in a unique learning environment and help contribute to the breakthrough mental health research and treatments of tomorrow

        Read More
    • Science & Research Staff Directory
      • Our Scientific Staff
      • Research Chairs at CAMH
    • Industry Partnerships & Technology Transfer Office
      • Spinoffs
      • Co-Development and Commercialization
    • Digital Innovation Hub
  • Education
    • Main Page
    • Continuing Education Programs and Courses
      • Find the Course That's Right for You

        Browse our entire selection of certificate programs, webinars and workshops.

      • Workplace Education and Consulting Services

        View our full list of workplace mental health workshops and consulting services

    • Collaborative Learning College
    • Simulation Centre
    • TIDES
    • Student Centre
    • Clinical & Research Opportunities for Professionals in Training
      • Clinical Psychology Training Programs
      • Community-Based Research Fellowship
      • Graduate & Post-Doctoral Fellowships in Public Health Policy
      • Clinical & Research Opportunities for Professionals in Training

        Study in a world-class setting to become a leader in the field of mental health.

    • Research in Education
      • Academic & Education Research Excellence
      • Health Equity and Inclusion Framework for Education and Training
    • Evaluation
    • Workplace Mental Health Workshops and Consulting
    • CAMH Education Contacts
  • Professionals
    • Main Page
    • Treating Conditions & Disorders
      • Adult ADHD
      • NAVIGATE - Treating Psychosis in Youth
      • CARIBOU - Treating depression in youth
      • Alcohol Use
      • Anxiety Disorders
      • Dementia
      • Depression
      • Suicide Risk
      • Fundamentals of Addiction
      • Intellectual & Developmental Disabilities
      • Mania
      • OCD
      • Opioid use and opioid use disorder
      • Perinatal Mood & Anxiety Disorders
      • Personality Disorders
      • Psychosis
      • Posttraumatic Stress Disorder
      • Sleep Disorders
      • Smoking Cessation
      • Virtual Mental Health
    • Professionals Projects
      • Climate Change and Mental Health
      • Health Care Access Research and Developmental Disabilities
      • Immigrant and Refugee Mental Health Project
      • Opioid Use in Primary Care Conference 2024
    • Networks
      • Psychiatry Partnerships with Northern Communities
    • Covid-19 Resources for Health Care Workers
    • Videos
    • Podcasts
  • Get Involved
    • Main Page
    • Ways to Donate
      • Give Monthly
      • Give In Memory or In Honour
      • Start a Fundraiser
      • Gifts of Celebration
      • Leave a Gift in Your Will
      • Employee Giving
      • Donate Goods & Services
      • Gifts of Securities
      • Canvassers & Callers
      • Make a one-time donation

        With your support, CAMH researchers are revolutionizing the ways we diagnose, treat, and prevent mental illness. Donate today.

    • Join the Cause
      • Corporate Partnerships
      • Business Leaders for Mental Health
      • CAMH Engage
      • womenmind
      • Visionary Society
      • Michael Wilson Society
      • Volunteer at CAMH
    • Making a Real Impact
      • Making a Real Impact

        Real stories of courage, hope and discovery. Made possible through your continued support of CAMH.

        Read More
  • Driving Change
    • Main Page
    • About CAMH
      • Leadership Team Directory
      • Performance & Accountability
      • The Role of CAMH Foundation
      • For Reporters
      • Events Calendar
      • For Our Neighbours
      • Contact CAMH
      • Careers at CAMH

        By working at CAMH, you can help people affected by mental illness and support their recovery. Join the team. Everyone who works at CAMH becomes an advocate for mental health.

    • The Crisis is Real
      • The Crisis is Real

        We are in the grips of a crisis that ruins health, threatens lives and hurts economies. Knowing the facts is the first step in creating hope.

      • Mental Health Statistics

        The latest facts and statistics on mental illness and addiction, who's affected and their impact on Canadians.

    • Addressing Stigma
      • Addressing Stigma

        Challenging the stigma associated with mental illness takes understanding, education and a closer look at our own attitudes toward health.

        Read More
    • The Mental Health Facility of the Future
      • The Mental Health Facility of the Future

        Turning what was once a walled institution into a symbol of hope for the future of mental health care.

      • Vision & Guiding Principles

        How do you replace an institution with an urban village? Lots of planning, imagination and a long-term commitment to serving patients, staff and the community.

      • History of Queen Street Site

        Our history—evolving from an asylum into a modern health facility with patients at the centre of care—is the history of mental health care in Canada.

    • Influencing Public Policy
      • Influencing Public Policy

        CAMH advocates for policies that are responsive to the needs of people with mental illness and addictions.

        Read More
    • Health Equity
      • Health Equity

        CAMH believes in the principle of equity. We respect the diversity of the individuals and communities we serve.

        Read More
    • Shkaabe Makwa
    • CAMH News & Stories
    • Strategic Plan
    • Contact Us
    • No One Left Behind
    • Join our team
    • Referral Form
    • Virtual Urgent Care
    • Accessibility

The Discovery Fund - Ideas

CAMH Logo
  • The Discovery Fund - Ideas
Back to top
CAMH logo
  • Overview
  • Governance and Research Priorities
  • People
  • Ideas
  • Discovery Platform
Back to top

The Discovery Fund supports new, promising research ideas and initiatives, encouraging collaboration across disciplines and areas of research, from the molecular, to the cellular, to the level of human experience and behaviour. These investments set in motion and accelerate platforms of convergence, supporting the best new ideas to improve the understanding, prevention, early detection and treatment of mental disorders, and bring discoveries to those that need them most to realize better outcomes in mental health.

Seed Funding

The Discovery Fund hosts an annual Seed Funding competition for CAMH scientists to develop innovative, high-risk/high-reward areas of research, with emphasis on external collaborations.  Check out the groundbreaking research projects supported through the competition.

2020/2021 Seed Funding Projects 

MahavirAgarwal

Project Title: Does abnormal insulin action in the brain underlie cognitive and metabolic dysfunction in schizophrenia?

Total Awarded: $200,000

Abstract: Background: Schizophrenia is associated with poor cognitive and metabolic outcomes that are not addressed adequately by currently available treatments leading to higher illness burden and lower quality of life. Brain insulin resistance has emerged as a potential mechanism underlying cognitive and metabolic disorders; preliminary evidence suggests that it might be a feature of schizophrenia as well. Direct markers of brain insulin action are not currently available. However, uptake of 18F-labelled fluorodeoxyglucose ([18F]-FDG) during a positron emission tomography (PET) scan following an intranasal insulin challenge can provide a surrogate marker. Aim: To examine if antipsychotic-naïve/free schizophrenia patients have greater brain insulin resistance compared to matched healthy controls. Hypotheses: Schizophrenia patients will have abnormal brain insulin action, evidenced by less [18F]-FDG uptake in response to intranasal insulin challenge, compared to healthy controls. Moreover, change in [18F]-FDG uptake will be negatively correlated with the severity of cognitive and metabolic dysfunction in patients with schizophrenia. Methods: Ten antipsychotic-naïve/free schizophrenia patients and ten matched healthy controls will participate in a single-blind crossover design, wherein all participants will undergo an overnight fast and two [18F]-FDG PET scans one week apart, one following intranasal placebo administration, and second with intranasal insulin challenge (160 IU) in a randomized order while receiving a somatostatin infusion. A cognitive battery and standardized symptom severity rating scale will also be administered. Significance: This pilot study can uncover aspects of schizophrenia disease process that are amenable to intervention using novel therapeutic strategies so as to target cognitive and metabolic abnormalities.

VanessaGonçalves

Project Title: Mitochondria, Inflammation and Genetics: A new approach for psychosis early detection and intervention

Total Awarded: $198,022.23

Abstract: Schizophrenia is a complex disorder with both clinical and biological complexity (heterogeneity), and to-date, effective diagnosis, treatment and prevention strategies are largely absent, in-spite of the recent success in identifying contributing genetic variants from the nuclear genome. Mitochondrial DNA (mtDNA) plays a crucial role in the brain suggesting that genetic variants in this system may contribute to the etiology of mental illnesses; previous studies of primary mitochondrial diseases have observed impairment in brain function and high prevalence of psychosis among cases. Here, we propose four interconnected studies that aim to reduce biological complexity in early detection and prevention of schizophrenia, by considering the mitochondrial DNA in addition to the chromosomal DNA. These include 1) conducting a largest to-date association analysis between mtDNA variants and schizophrenia using the worldwide Psychiatric Genomics Consortium (PGC) data with over 50,000 cases, 2) investigating mitochondria and chromosome gene-gene interactions, including those involving the X-chromosome, 3) evaluating one risk score made up of many genes to predict schizophrenia when incorporating mtDNA variants and their interactions, and 4) exploring the use of circulating cell free mtDNA in the blood as a marker for the presence of mitochondrial abnormalities and inflammation in schizophrenia. Access to mtDNA data from PGC, the largest schizophrenia dataset, allows us to perform the analyses with strong statistical power. The results from our studies will likely identify new mtDNA variants from the previously over-looked mitochondrial system, which could lead to increased accuracy in disease prediction and personalized treatment of schizophrenia and other psychosis-related disorders.

IshratHusain

Project Title: Astrocytes as targets of lithium treatment in bipolar disorder: a [11C]SL2511.88 positron emission tomography study

Total Awarded: $199,991

Abstract: Up to 50% of patients with bipolar disorder (BD) experience recurrent mood episodes on currently available treatments. Thus, the development of new treatment approaches is a major health priority. A growing number of studies demonstrate that: (1) BD is associated with abnormal inflammatory and oxidative processes linked to astrocyte dysfunction; (2) immunomodulatory agents may improve mood symptoms. However, results of randomized controlled trials (RCTs) of these agents in BD have been mixed and none have incorporated brain imaging to understand their putative mechanism of action. Lithium has been widely used in the treatment of BD for more than 50 years; it remains a first-line treatment for both manic and depressive episodes. However, its specific mode of action is still unclear. Some evidence indicates that lithium has both immunomodulatory and anti-oxidative actions and regulates astrocytes. We propose to investigate the effect of lithium on astrocytes in BD using positron emission tomography (PET). We are completing pilot [11C]SL2511.88 scanning in 20 adults with BD to assess brain MAO-B volume distribution (VT) as an index of the baseline measure of astrocytes. With the support of seed funding from the Discovery Fund, we propose to rescan 20 participants with BD after 6 months of lithium treatment to determine whether clinical outcomes are associated with a change in astrocytes as quantified by MAO-B VT. This study has the potential to elucidate the impact of lithium on pathophysiological mechanisms in BD. If it establishes that astrocytes can be used as biomarkers and are potential therapeutic targets in BD, it will be a foundation for a precision medicine approach in the treatment of BD.

JamesKennedy

Project Title: Identifying suicidality subtypes using machine learning and genomic data

Total Awarded: $200,000

Abstract: Background: There are over 800,000 suicide deaths worldwide each year. With over 3,500 suicides and 70,000 suicide attempts each year, it is the ninth leading cause of mortality in Canada. Suicidal thinking (ideation) and behaviour (SIB) is very complex and is likely affected by many variables, including genetic factors. Finding genetic factors for SIB may require separating SIB into subtypes to reduce complexity. Objectives: We aim to collect data from 550 participants and evaluate them on their SIB and a number of endophenotypes. We aim to uncover SIB subgroups based on these endophenotype measures. Then, we aim to find genes relating to each of the SIB subgroups.Hypotheses: (1) Patients cluster into SIB subtypes based on the endophenotypes. (2) Genetic variants, in the form of genes, gene-sets, and risk scores calculated from thousands of genes, each with small effect, are associated with SIB subtypes. Methods: Participants will be assessed through a series of questionnaires about their history of SIB (Columbia Suicide Severity Rating Scale (CSSRS)), stressful life events, personality, as well as through several neurocognitive tasks. A number of machine learning algorithms will be used to cluster participants based on these clinical assessments. A preliminary genetic analysis (gene-based, gene-set, and multigene-risk score) will be conducted across these SIB subtypes.

Significance: Findings from this study will provide for a better understanding of the biology of one or more SIB subtypes, which will inform the design of future suicide studies and the development of subtype-specific drug therapies and prevention.

YuliyaKnyahnytska

Project Title: Neural Correlates of anti-suicidal response to ketamine in treatment resistant bipolar depression

Total Awarded: $168,821.60

Abstract: The overall aim of this proposal is to investigate ketamine for the treatment of suicidality in bipolar depression and to use neurophysiological measures of NMDA neurotransmission to identify key biological targets of ketamine treatment response. Suicide is one of the top ten leading causes of death with rates progressively increasing making suicide a critical public health issue. Suicidality refers to a combination of suicidal thoughts, intent, and plan, and is the most lethal symptom affecting patients with depression. Bipolar disorder is one of the most incapacitating psychiatric conditions and one of the most costly to society. Researchers estimate between 25-60% of those with bipolar depression will attempt suicide at least once in their lifetime, and about 10-15% will die by suicide. Several interventions, such as lithium, clozapine, electroconvulsive therapy, and cognitive behavioral therapy demonstrated anti-suicidal properties; however, these treatments are often ineffective, difficult to tolerate or take months to have a full effect. Therefore, newer and more effective treatments for suicidality in bipolar disorder are needed. Ketamine is a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist, which has shown rapid antidepressant and anti-suicidal effects. The development of an effective intervention for suicidality in BD remains a major therapeutic challenge and opportunity. Ketamine represents a promising treatment due to its rapid effect and for targeting underlying NMDA neurophysiological mechanisms. Establishing biological markers of treatment response is essential to enhance our understanding of both illness and treatment mechanisms.

MatthewSloan

Project Title: Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder: A Human Laboratory Study

Total Awarded: $199,470

Abstract: Alcohol use is one of the leading causes of death and disability worldwide. Despite this, only three medications are approved to treat alcohol use disorder (AUD) in Canada and these medications are only effective in a subset of individuals. Developing new and effective pharmacotherapies is essential to reduce the rate of disability associated with AUD. Cannabidiol, a non-psychoactive component of the Cannabis Sativa plant, shows potential promise. Studies have demonstrated that cannabidiol decreases alcohol preference, self-administration, and relapse-like behaviours in rodents. However, despite these exciting findings, the effects of cannabidiol have not been studied in humans with AUD. The purpose of this pilot study is to determine the effects of cannabidiol on craving and alcohol self-administration in this population. We hypothesize, based on the preclinical findings, that cannabidiol will reduce craving and alcohol self-administration. We propose to recruit 28 non-treatment seeking subjects with AUD for a within-subject trial. Participants will be randomized to cannabidiol or placebo in a counterbalanced order for two 7-day treatment periods. On day 7 of each treatment period, subjects will complete an alcohol self-administration task that has been shown to identify effective pharmacotherapies for AUD. Craving, subjective response to alcohol, and alcohol consumption will be measured. If cannabidiol effectively reduces craving and alcohol self-administration, it could potentially be used either alone or in combination with approved pharmacotherapies for AUD. The addition of another effective anticraving medication would be a major clinical advance that could substantially reduce the rate of disability associated with AUD.

GillianStrudwick

Project Title: Co-producing interventions to improve the adoption of OpenNotes in Ontario mental health contexts

Total Awarded: $199,120

Abstract: The purpose of the study is to co-produce and contextualize interventions that improve the adoption of OpenNotes by providers and patients. Our pilot research at the Centre for Addiction and Mental Health (CAMH) has identified from patients and providers the specific interventions that may be useful, and that should be developed for the Ontario context. Therefore, the aims of our study are to: 1) Identify the needs of mental health providers and patients in their use of OpenNotes at three distinct stages of adoption (before, during, and after implementation) building on our pilot data from CAMH; 2) Categorize the needs from the first objective to identify agreements and differences in the requirements for OpenNotes use from providers and patients. The differences will then be mapped to the interventions; 3) Contextualize the interventions from the second objectives through co-production with user groups. We will then apply for funding to evaluate the implementation of the interventions at the various study sites. The study will be conducted at four large organizations in Ontario that serve people with mental illness (two urban, one semi-urban, one rural) over a period of 2 years. The interventions to be co-produced consist of an electronic toolkit, short videos and podcasts. The present study will act as a catalyst for future digital mental health initiatives, where Ontario organizations can work together to support people with mental illness.

JohnVincent

Project Title: Identification and assessment of therapeutic potential of small molecules as allosteric modulators or chaperones for the Rett syndrome protein MECP2

Total Awarded: $200,000

Abstract: Background: Rett syndrome (RTT) is the second most common genetic cause of intellectual disability in girls, and is caused by mutations in the X-linked gene MECP2. ~40% of RTT is caused by nonsense mutations which truncate the protein, and ~40% are caused by missense mutations (substitution of one amino acid for another). MECP2 is a transcriptional regulator, and current therapeutics research is mainly focussed on the downstream effects of the resulting dysregulation. Objectives: This proposal aims to develop compound to reverse MECP2 protein degradation, and/or restore its function. Hypothesis: small molecules or peptides with ability to bind to MECP2 can restore its activity and/or stabilize the protein. Methods: We aim to utilize, in parallel, a. computational screening for small molecules, and b. screening for short peptides, targeting wild-type MECP2, and the most common missense and nonsense mutations. We will assay selected molecules for ability 1. to recover DNA-binding and/or chromatin-clustering and gene regulation abilities of MECP2; 2. to stabilize MECP2 protein; 3. to recover normal neuronal morphology. For this purpose we have established a series of DNA binding and chromatin assays. We will also generate brain cells with the relevant MECP2 mutations using CRISPR/cas9 editing, so we can measure MECP2 mRNA and protein levels, before and upon addition of our selected compounds. Significance:  This project outlines the first steps to develop precision therapeutic compounds to treat RTT. This approach will spearhead a move towards precision therapeutics for other autism or intellectual disability genes.

Previously awarded projects:

  • 2019/2020 Seed Funding Projects
  • 2018/2019 Seed Funding Projects

Attracting investments

The Discovery Fund allows for opportunities to secure external peer reviewed awards for research, offering matching funds to successful applicants.  Some of the supported initiatives include:

  • Dr. Leon French (Canada Foundation for Innovation match – John R. Evans Leaders Fund): Genomic Portal for Polygenic Molecular Maps of the Brain
  • Dr. Sanjeev Kumar (Brain Canada match): The Toronto Dementia Research Alliance (TDRA) Dementia Database: A platform in neurodegenerative diseases
  • Dr. Tarek Rajji (Brain Canada match): Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia
  • Dr. Nelson Shen, Supervisor: Dr. Gillian Strudwick (Health Systems Impact Fellowship match): Patient and Family Engagement in Health IT Initiatives

Transformative Initiatives

The Discovery Fund invests in several large-scale initiatives transforming patient care:

  • The Toronto Adolescent and Youth (TAY) CAMH Cohort Study: The TAY CAMH Cohort study will recruit and follow 3,000 youth over five years to answer the central questions of who is at highest risk of developing psychosis, and what is the relationship between those risk trajectories and functional outcomes.

Can we count on your support?

Donate to help us improve mental health care for everyone.

Follow us
  • Patient and Family Care
  • Health Info
  • Science and Research
  • Education
  • Professionals
  • Get Involved
  • Driving Change
  • About CAMH
  • Job Openings
  • Purchase Publications
  • Referral Form
  • For Reporters
  • Donor Services
  • Events

CAMH Switchboard

From the GTA: 416 535-8501


Toll-free: 1 800 463-2338

To Access CAMH Clinical Services

416 535-8501, press 2

We have multiple locations. Find directions.

Map of CAMH's Queen Street Site
  • Staff Tools

Copyright 2025 CAMH

  • Terms of Use
  • Accessibility
  • Site Map

Keep in touch with CAMH

Keep your finger on our pulse – latest CAMH news, discoveries and ways to get involved delivered to your inbox.

Please select a newsletter

Please complete the following:

    Required Fields

    Please select a newsletter option

    Please input a first name

    Please input a last name

    Please input an email address

    By clicking Sign Up below, I consent to receive electronic communications (as selected above) from CAMH and CAMH Foundation. To unsubscribe at any time click the link in our mailing or email: unsubscribe@camh.ca

    Please agree to the Terms of Use

     

    Thanks for Subscribing.

    We look forward to keeping you informed, inspired and involved in all things CAMH.

    Help us change mental health care forever.

    Every donation moves us closer to a future where no one is left behind.

    $
    Other Ways to Give
    Join our team